ESTABLISHMENT LABS HLDGS

Shares of Establishment Labs rose to a new 52-week high of $90.54 after the stock gained 105% over the past year. The company reported revenue growth of 35% to $230 million over the last twelve months; Q1 2026 revenue was $59.9 million, topping expectations, while earnings per share missed estimates with a loss of $0.45. Establishment Labs appointed Taylor Harris to the board of directors, will be added to the Russell 2000, and received a buy rating from TD Cowen. » More on de.investing.com

JW Asset Management indirectly sold 90,533 shares of Establishment Labs via open-market trades from May 26–28, raising about $6.64 million at a weighted average price of $73.31. The sales reduced the fund's indirect holdings to 2,890,582 shares, dropping its stake below the 10% threshold, though it remains a large shareholder. The disposition exceeded the fund's typical sale size but is consistent with a disciplined reduction; Establishment Labs has since posted strong results, raised 2026 guidance and was added to the Russell 2000. » More on finance.yahoo.com

Establishment Labs reported Q1 revenue of $59.9 million and adjusted EBITDA of $1.2 million, marking its third consecutive quarter of positive adjusted EBITDA and 45% revenue growth year over year. U.S. revenue surged to $19.6 million (up 216% YoY) as the company surpassed 1,700 U.S. accounts and launched the Preservé minimally invasive platform, which generated $9.1 million in the quarter. Management raised full-year 2026 revenue guidance to $266.5–$268.5 million and now expects minimally invasive revenue to exceed $35 million in 2026. The company refinanced its credit facility to $265 million (8.75% with PIK options), ended the quarter with $68.1 million cash and expects to reach cash-flow positive in H2 2026 without equity financing. » More on finance.yahoo.com